Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.58 |
| ▸ | TNNI3K | Q59H18 | 9/20 | 0.58 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.49 |
| ▸ | BRAF | P15056 | 4/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22592313 | 0.85 | KDR (0.67) | KDRTNNI3KMAP2K7MAPK14BRAF | |
| SCHEMBL3183099 | 0.83 | KDR (0.51) | KDRTNNI3KMAP2K7MAPK14BRAF | |
| SCHEMBL14540942 | 0.81 | KDR (0.56) | KDRTNNI3KMAP2K7MAPK14BRAF | |
| SCHEMBL12664956 | 0.80 | SCN9A (0.52) | KDRTNNI3KMAP2K7CYP2C19 | |
| SCHEMBL3182550 | 0.80 | MEN1 (0.66) | TNNI3KRAF1CYP2C19 | |
| SCHEMBL3171765 | 0.79 | RAF1 (0.57) | KDRTNNI3KMAP2K7MAPK14BRAF | |
| SCHEMBL1896051 | 0.79 | MEN1 (0.55) | KDRTNNI3KMAPK14BRAFRAF1 | |
| SCHEMBL4931460 | 0.79 | KDR (0.73) | KDRTNNI3KMAP2K7MAPK14BRAF | |
| SCHEMBL4912985 | 0.78 | KDR (0.59) | KDRTNNI3KMAP2K7MAPK14BRAF | |
| SCHEMBL4795754 | 0.78 | SMN1; SMN2 (0.48) | KDRTNNI3KMAPK14BRAFCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | KDR 3898/4885TNNI3K 340/4885MAP2K7 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.